NxStage Medical (NXTM) Stock Rating Lowered by BidaskClub
NxStage Medical (NASDAQ:NXTM) was downgraded by stock analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued on Tuesday.
Several other research firms also recently weighed in on NXTM. ValuEngine raised shares of NxStage Medical from a “hold” rating to a “buy” rating in a research report on Saturday, June 2nd. Zacks Investment Research downgraded shares of NxStage Medical from a “hold” rating to a “sell” rating in a research report on Saturday, August 11th. Two equities research analysts have rated the stock with a sell rating and three have given a hold rating to the company. NxStage Medical has an average rating of “Hold” and a consensus target price of $30.00.
NXTM opened at $28.19 on Tuesday. The stock has a market capitalization of $1.85 billion, a PE ratio of -128.14 and a beta of -0.05. NxStage Medical has a 1-year low of $22.70 and a 1-year high of $28.75.
NxStage Medical Company Profile
NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.
Featured Story: How to Track your Portfolio in Google Finance
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.